Sign in
Not yet recruitingPhase 4

Antibiotic Therapy In Respiratory Tract Infections

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France10 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
310 people, planned
Started
Nov 2026
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Predetermined treatment duration
  • Variable treatment duration
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Patient aged 18 years or more
  • Has given written informed consent
  • Affiliated to Health insurance
  • Is able to take oral treatment
  • Presenting with suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:; Fever (temperature > 38°C); Dyspnea; Cough; Production of purulent sputum; Crackles; Radiological evidence of a new infiltrate (on chest X-ray or CT scan)
  • In need for antibiotic treatment targeting respiratory tract, according to the physician in charge
  • No other site of infection besides respiratory

Who cannot take part

  • Baseline oxygen saturation < 90% or home oxygen therapy
  • More than 24 hours of antibiotics prior to consultation
  • Any other infection necessitating concomitant antibiotic treatment
  • Concomitant steroid treatment only for patients treated with fluoroquinolones antibiotics
  • Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, arterial hypertension, atherosclerosis only for patients treated with fluoroquinolones antibiotics
  • Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)
  • Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, immunosuppressive treatments or corticosteroids (prednisolone equivalent) > 10 mg/day, transplant, myeloma, lymphoma, known HIV and CD4<400/mm3, sickle-cell disease, Child-Pugh class C cirrhosis)
  • All subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation:
  • Hospitalization following consultation
  • Suspected or confirmed legionellosis
  • Atrial fibrillation / constitutive tachycardia
  • Patients for whom the investigator plans to prescribe a fluoroquinolone (including levofloxacin) for the treatment of community-acquired pneumonia
  • Contraindications to the study antibiotics
  • Pregnancy
  • Breastfeeding
  • Life expectancy < 1 month
  • Patient under legal guardianship or without healthcare coverage
  • Homeless patient
  • Patient enrolled in another interventional clinical trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary aim: to demonstrate that stopping antibiotic treatment in patients diagnosed with acute community acquired pneumonia (CAP) based on clinical response has a non-inferior efficacy 15 days after start of treatment, compared to a conventional predetermined duration left to the physician's judgement, in adults treated in the community setting.

Read full original descriptionShow less

Secondary aims: To compare the 2 study arms on:

1. Clinical success at late follow up (Day 30), 2. Duration of antibiotic treatment, 3. Frequency and severity of adverse events, 4. Patient's pneumonia symptoms and quality of life.

The 2 groups in the trial

  • Physician's prescriptionExisting treatment, for comparison

    Antibiotic treatment duration according to physician, following the French national guidelines (www.has-sante.fr/upload/docs/application/pdf/2024-12/reco362\_fiche\_memo\_\_durees\_antibiotherapies\_pac\_adulte\_mel\_dec\_2024.pdf )

    Treatment: Predetermined treatment duration

  • Duration according to stabilityTreatment being tested

    Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%). Minimum of duration of antibiotic treatment: 3 days.

    Treatment: Variable treatment duration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Controlled Randomized, Open Label, Multicenter, Non-inferiority Trial Evaluating an Individualized Antibiotic Duration Treatment Based on Patient Clinical Response, Evaluated Through Connected Devices, for Community Acquired Pneumonia in the Community Setting
Record updated
12 November 2026